Abstract
BackgroundMethotrexate is the mainstay DMARD in RA treatment1. Despite its effectiveness, additional DMARDs are often required to achieve the recommended goals of low disease activity/remission1. Given the clinical implications of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
